When building your watch list, look for stocks with an 80 or higher RS Rating. Agios Pharmaceuticals just met that criteria with a new score of 83.
IBD's unique RS Rating measures technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the last 52 weeks matches up against other publicly traded companies.
Over 100 years of market history shows that the best stocks typically have an RS Rating of above 80 as they launch their biggest price moves.
Looking For The Best Stocks To Buy And Watch? Start Here
Agios Pharmaceuticals is not currently offering a proper buying opportunity. See if the stock goes on to build a chart pattern that could spark a new run.
Agios Pharmaceuticals showed 0% earnings growth in the latest quarterly report. Revenue gains came in at 21%.
The company holds the No. 96 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, ADMA Biologics and Exelixis are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
